Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.49 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | CD44 | P16070 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11328824 | 0.82 | PNMT (0.45) | PNMTADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL3600557 | 0.81 | PNMT (0.49) | PNMTADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL3606170 | 0.81 | HTR2A (0.50) | PNMTADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL3597388 | 0.79 | HTR2C (0.47) | PNMTADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL6610894 | 0.73 | HTR2C (0.48) | PNMTADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL30487392 | 0.72 | HTR2A (0.54) | PNMTADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL17008811 | 0.72 | PTGER4 (0.31) | — | |
| SCHEMBL19642911 | 0.71 | HTR2C (0.47) | PNMTADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL31173285 | 0.71 | HTR2C (0.77) | PNMTADRA2AHTR2CHTR2AHTR2B | |
| SCHEMBL29507169 | 0.71 | PNMT (0.58) | PNMTADRA2AHTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| WO-2007109182-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | PNMT 4045/4885ADRA2A 543/4885HTR2C 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.